|
|
|
| Bibliometric analysis of the research of liver cancer stem cell based on CiteSpace and VOSviewer#br# |
| ZHANG Zhichun1 SUN Lichao2 SUN Qiuyue1 TIAN Gu3 |
1.Key Laboratory, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
2.National Cancer Center National Clinical Research Center for Cancer State Key Laboratory of Molecular Oncology of Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
3.International Exchange Office, National Cancer Center National Clinical Research Center for Cancer Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
|
|
|
Abstract Objective To explore the research hotspots and research trends in the field of liver cancer stem cells (LCSCs) in the past 10 years through the bibliometric analysis of LCSCs. Methods The annual distribution of articles published, countries, institutions, authors, journals, cited situation, and keywords of articles published from 2011 to 2020 were performed visual analysis through CiteSpace and VOSviewer based on the Web of Science core database. Results From 2011 to 2020, the number of LCSCs-related articles published was 1000, and the number of LCSCs-related articles published showed an overall increasing trend. The top five countries in the number of published articles were China, United States, Japan, South Korea, and Italy. The top five research institutions in the number of published articles were Second Military Medical University, Sun Yat-sen University, Fudan University, University of Hong Kong, and Shanghai Jiao Tong University. The top five authors in the number of published articles were Stephanie Ma, Taro Yamashita, Jia Fan, Hongyang Wang, and Shuichi Kaneko. The top five publications in the number of published articles were Oncotarget, Hepatology, Cancer Letters, PLoS One, and Scientific Reports. In the cited literatures, Taro, etc. 2009 published “EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features” was cited the most frequently; studies on dry markers identified by LCSCs, studies on transcription factors, long non-coding RNA, microRNAs, oncogenes, signaling pathways that regulate LCSCs and other sides were the research hotspots in the field of LCSCs; LCSCs stem research-targeted LCSCs therapy research-LCSCs biological mechanism research was the research trend of LCSCs, the research on inhibitors targeting LCSCs was the focus of LCSCs research. Conclusion The research of genes and signal pathways regulating LCSCs is a research hotspot in the field of LCSCs, and the research of drugs targeted LCSCs is a key research direction in the field of LCSCs.
|
|
|
|
|
|
[1] 孙可欣，郑荣寿，张思维，等.2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤，2019，28（1）：1-11.
[2] Hollebecque A，Malka D，Ferte C，et al. Systemic treatment of advanced hepatocellular carcinoma：from disillusions to new horizons [J]. Eur J Cancer，2015，51：327-339.
[3] Liu K，Lee J，Kim JY，et al. Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells [J]. Molecular Cell，2017，68（2）:281-292.
[4] Yang L，Shi P，Zhao G，et al. Targeting cancer stem cell pathways for cancer therapy [J]. Signal Transduct Target Ther，2020，5（1）：8.
[5] Yao L，Hui L，Yang Z，et al. Freshwater microplastics pollution：Detecting and visualizing emerging trends based on Citespace Ⅱ [J]. Chemosphere，2020，245：125627.
[6] 高凯.文献计量分析软件VOSviewer的应用研究[J].科技情报开发与经济，2015，22（12）：95-98.
[7] Yamashita T，Ji J，Budhu A，et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features [J]. Gastroenterology，2009， 136（3）：1012-1024.
[8] 李秀华，郝新，邓永红，等.应用aMAP评分评估基层医院慢性肝病人群的肝癌发生风险[J].中华肝脏病杂志，2021，29（4）：332-337.
[9] Villanueva A. Hepatocellular Carcinoma [J]. N Engl J Med，2019，380（15）：1450-1462.
[10] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[11] Zhu XD，Tang ZY，Sun HC. Targeting angiogenesis for liver cancer：Past，present，and future [J]. Genes Dis，2020， 7（3）：328-335.
[12] Anwanwan D，Singh SK，Singh S，et al. Challenges in liver cancer and possible treatment approaches [J]. Biochim Biophys Acta Rev Cancer，2020，1873（1）：188314.
[13] Ma S，Chan KW，Hu L，et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells [J]. Gastroenterology，2007，132：2542-2556.
[14] Yang ZF，Ho DW，Ng MN，et al. Significance of CD90+ cancer stem cells in human liver cancer [J]. Cancer Cell，2008，13（2）：153-166.
[15] Shan J，Shen J，Liu L，et al. Nanog regulates self-renewal of cancer stem cells through the insulinlike growth factor pathway in human hepatocellular carcinoma [J]. Hepatology，2012，56：1004-1014.
[16] Wu J，Zhu P，Lu T，et al. The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling [J]. J Hepatol，2019，70（5）：918-929.
[17] Nault JC，Zucman-Rossi J. Genotype-phenotype relationships in hepatocellular carcinoma：p53 inactivation promotes tumors with stem cell features [J]. Gastroenterology，2012，142（5）：1066-1069.
[18] Kuo KK，Lee KT，Chen KK，et al. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer [J]. Stem Cells，2016，34（11）：2613-2624.
[19] Huang M，Chen C，Geng J，et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma [J]. Cancer Lett，2017，398：12-21.
[20] Chen CL，Uthaya Kumar DB，Punj V，et al. NANOG Metab-olically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism [J]. Cell Metab，2016，23（1）：206-219.
[21] Machida K. Pluripotency Transcription Factors and Meta-bolic Reprogramming of Mitochondria in Tumor-Initiating Stem-like Cells [J]. Antioxid Redox Signal，2018，28（11）：1080-1089.
[22] Liu Y，Qi Y，Bai ZH，et al. A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways [J]. Acta Pharmacol Sin，2017，38（1）：120-132.
[23] Sun J，Luo Q，Liu L，et al. Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway [J]. Toxicology，2017，384：1-10.
[24] Maehara O，Ohnishi S，Asano A，et al. Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines [J]. Neoplasia，2019，21（6）：545-556.
[25] Tsai CF，Hsieh TH，Lee JN，et al. Curcumin Suppresses Phthalate-Induced Metastasis and the Proportion of Cancer Stem Cell（CSC）-like Cells via the Inhibition of AhR/ERK/SK1 Signaling in Hepatocellular Carcinoma [J]. J Agric Food Chem，2015，63（48）：10388-10398.
[26] Wang HY，Zhang B，Zhou JN，et al. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex [J]. Cell Death Dis，2019，10（6）：453. |
|
|
|
